Key clinical recommendation	SOR labels	References
The updated ACC/AHA guideline recommends use of the thienopyridine clopidogrel (Plavix) in patients who cannot tolerate aspirin (ACC/AHA class I).	A	2, 3, 17
The updated ACC/AHA guideline considers the use of clopidogrel in addition to aspirin to have a class I indication in patients with UA/NSTEMI who are undergoing an early noninterventional or interventional approach and are not at high risk for bleeding.	A	2, 3, 18, 19
When elective coronary artery bypass grafting is planned, clopidogrel should be withheld for five to seven days.	C	2, 3
Platelet glycoprotein IIb/IIIa inhibitors have an ACC/AHA class I indication in patients for whom catheterization and percutaneous coronary intervention are planned. These agents should be administered in addition to aspirin and heparin.	A	20–23, 25
Anticoagulation with unfractionated heparin or low-molecular-weight heparin for patients with UA/NSTEMI has an ACC/AHA class I indication. The heparin is to be used in addition to aspirin or clopidogrel.	A	27